Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:QURE 24 September 2025 - 9 March 2026

Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

Atara Biotherapeutics shares jumped 18% Monday after reports that FDA biologics chief Vinay Prasad will depart in April. The move follows the agency’s January rejection of Atara’s EBVALLO therapy for a rare blood cancer, which wiped out 56% of the stock’s value. Atara and partner Pierre Fabre have requested a Type A meeting with the FDA to revisit the decision. Atara ended 2025 with $8.5 million in cash.
9 March 2026
····
uniQure stock jolts higher again after FDA biologics chief set to exit

uniQure stock jolts higher again after FDA biologics chief set to exit

uniQure shares surged 34% to $14.27 in U.S. premarket trading Monday after news that FDA biologics chief Vinay Prasad will step down in April. The move follows a dispute over the agency’s demand for a new sham-surgery trial of uniQure’s Huntington’s gene therapy. The FDA has not agreed to approve the treatment based on current data. uniQure ended 2025 with $622.5 million in cash and investments.
9 March 2026
·
uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

uniQure shares jumped about 15% to $23.50 in pre-market trading Dec. 16 after a 10% after-hours gain, despite ongoing FDA uncertainty over its Huntington’s disease gene therapy, AMT-130. The FDA told uniQure its Phase I/II data are “currently unlikely” to support a Biologics License Application, prompting the company to seek further talks in early 2026.
16 December 2025
··
UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure Stock Plunges 50% on FDA Shocker – What’s Next for QURE’s Gene Therapy Ambitions?

uniQure shares plunged over 50% after the FDA said data for its Huntington’s disease gene therapy is not sufficient for approval, reversing earlier guidance. The stock dropped from about $68 to $34, wiping out roughly half its market value. Analysts called it a major regulatory setback, with some cutting price targets. Shareholder rights law firms launched investigations following the 57% one-day decline.
4 November 2025
·
UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure shares plunged nearly 65% to $23–24 midday Nov. 3 after the FDA ruled current Huntington’s trial data insufficient for approval, erasing billions in market value. The company had raised $345 million in September at $47.50/share following a surge on positive trial results. Q2 revenue was $5.3 million, with a net loss of $37.7 million. Cash reserves rose to about $550 million after the equity raise.
3 November 2025
··
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

A One‑Time Brain Gene Therapy Just Slowed Huntington’s by 75%—Is This the Turning Point Families Have Waited For?

Early trial data show AMT-130 gene therapy slowed Huntington’s disease progression by 75% at 36 months in high-dose patients compared to controls. Treated participants’ neurofilament light levels dropped below baseline. The neurosurgical procedure lasts 12–20 hours. The developer plans a U.S. regulatory filing in 2026 if results hold.
26 September 2025
·
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

Gene Therapy Breakthrough: uniQure’s QURE Stock Skyrockets on Huntington’s Triumph

uniQure shares jumped over 150% on September 24, 2025, after its Huntington’s gene therapy slowed disease progression by 75% in a landmark trial. The company’s market value rose above $2.5 billion. uniQure plans to seek FDA approval in early 2026 and secured a $175 million credit facility to support commercialization. Cash reserves reached $377 million as of June 30, 2025.
24 September 2025
····
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

uniQure reported its gene therapy AMT-130 slowed Huntington’s disease progression by 75% over three years in high-dose patients. Trading in QURE shares was halted on volatility; the stock jumped from $4.45 to the mid-teens. The company secured a $175 million loan to fund AMT-130’s potential launch. Wall Street analysts rate the stock “Buy,” with targets averaging $37–$40.
24 September 2025
···

Stock Market Today

  • Oppenheimer Raises Target Hospitality Price Target to $18, Sees 20% Upside
    April 9, 2026, 10:38 AM EDT. Oppenheimer lifted its price target for Target Hospitality (NASDAQ:TH) stock from $11 to $18, signaling a 20% potential upside. The firm rated the stock as outperform, reflecting growing confidence amid mixed analyst views. Other firms like Texas Capital and Stifel Nicolaus also upgraded ratings, while Weiss maintained a sell rating. Target Hospitality's shares opened Thursday at $14.99, near a 12-month high. Despite a recent quarterly earnings miss with a loss of $0.15 per share, revenue topped expectations at $89.78 million. The stock holds a market cap of $1.5 billion and a negative P/E ratio due to losses. Insider selling occurred in January, with EVP Heidi Diane Lewis reducing holdings by 6.39%. Institutional interest remains active, marking a nuanced outlook for the company in the hospitality sector.

Latest article

Grab Holdings Bets on AI as Group Ride Tool Targets 40% Lower Fares

Grab Holdings Bets on AI as Group Ride Tool Targets 40% Lower Fares

9 April 2026
Grab Holdings launched 13 new AI-powered products in Jakarta, including a “Group Ride” feature that can cut fares by up to 40% for shared routes. CEO Anthony Tan said the tools aim to offset rising fuel costs and support demand as households tighten spending. The company’s 2026 revenue and profit forecasts remain below analyst expectations. Grab’s $600 million deal to buy Foodpanda Taiwan is pending regulatory approval.
Nokia Oyj AI Data Center Push Gets Lift From Fifth Straight GigaOm Leader Ranking

Nokia Oyj AI Data Center Push Gets Lift From Fifth Straight GigaOm Leader Ranking

9 April 2026
Nokia was named a Leader and Outperformer in GigaOm’s 2026 Radar for data center switching for the fifth year in a row, competing with Cisco, Arista, and HPE Juniper. Shares fell 1.05% in Helsinki ahead of Thursday’s annual meeting, where board changes and a dividend of up to 14 euro cents per share will be considered.
American Airlines Faces FAA Fine Over Drug-Testing Lapses in New Test for 2026 Turnaround

American Airlines Faces FAA Fine Over Drug-Testing Lapses in New Test for 2026 Turnaround

9 April 2026
The FAA proposed a $255,000 civil penalty against American Airlines, alleging the carrier allowed 12 flight attendants who tested positive for drugs or alcohol to return to safety-sensitive duties before completing required follow-up tests. The alleged violations occurred from May 2019 to December 2023. American has 30 days to respond. The airline said it is reviewing the notice.
Hologic goes private: Blackstone, TPG close buyout and name José Almeida CEO

Hologic goes private: Blackstone, TPG close buyout and name José Almeida CEO

9 April 2026
Blackstone and TPG closed their $17.3 billion acquisition of Hologic on April 7, with José Almeida replacing Steve MacMillan as CEO. Hologic shares were suspended before trading that day and will be removed from the S&P 500 before Thursday’s open. Former shareholders will receive $76 per share in cash plus a contingent value right worth up to $3 more if revenue targets are met.
When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

9 April 2026
Brent crude rebounded 3% Thursday despite a U.S.-Iran ceasefire, with the Strait of Hormuz still nearly shut and only one oil-products tanker passing in 24 hours. U.S. gasoline averaged $4.166 a gallon on April 9, and AAA said prices could drop slowly. North Sea Forties crude hit a record $146.43 a barrel. The U.S. EIA expects Hormuz flows may take months to recover.
Go toTop